logo
Plus   Neg
Share
Email

Cisco Systems Q3 Results Beat Wall Street

Silicon Valley giant Cisco Systems Inc., (CSCO) Wednesday reported a profit and revenues for the third quarter that trumped Wall Street analysts estimates.

The San Jose, California-based networking-equipment maker reported third-quarter profit of $3.04 billion or $0.69 per share, compared to last year's profit of $2.69 billion or $0.56 per share.

Adjusted earnings for the quarter were $0.78 per share, up from $0.66 per share last year. On average, 26 analysts polled by Thomson Reuters estimated earnings of $0.77 per share for the quarter.

Revenues for the quarter grew 6 percent to $12.96 from $12.46 billion last year. Analysts had a consensus revenue estimate of $12.89 billion for the quarter.

"Our strong performance in the quarter was across the business, reflecting our customers' confidence in our strategy, business model and market-leading portfolio," said CEO Chuck Robbins. "Technology is at the heart of our customers' strategies and we are building the technology to help them achieve their business objectives."

Looking forward to the fourth quarter, Cisco expects adjusted earnings of $0.80 to $0.82 per share with revenue growth of 4.5 to 6.5 percent. Analysts currently expect earnings of $0.81 per share, with revenue growth of 3.50 percent.

CSCO closed Wednesday's trading at $52.44, up $0.42 or 0.81%, on the Nasdaq. The stock further gained $1.40 or 2.67% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT